Actuate Therapeutics (ACTU)

Executive Summary

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company developing elraglusib (9-ING-41), a first-in-class GSK-3β inhibitor for hard-to-treat cancers. GSK-3β is a key regulator of tumor growth and immune evasion, and elraglusib targets both cancer cell proliferation and anti-tumor immunity. The company aims to overcome resistance to standard therapies, including chemotherapy and immunotherapy. As of mid-2026, Actuate has a market capitalization of ~$75 million and no approved products. The lead asset is currently in Phase 2 clinical trials for indications such as pancreatic cancer, lymphoma, and other solid tumors. While early clinical data have shown promising single-agent activity and tolerability, the company faces significant development risk and cash burn. Actuate's near-term value hinges on successful trial results and potential partnerships or financing to support future development. Key upcoming catalysts include data readouts from ongoing Phase 2 studies and potential regulatory designations.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 data readout for elraglusib in pancreatic cancer30% success
• Q4 2026FDA orphan drug designation or fast track status for lead indication60% success
• TBDPotential licensing or collaboration agreement to extend cash runway20% success